Venus Bioceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.50 M
as on 16-12-2024
- Paid Up Capital ₹ 5.10 M
as on 16-12-2024
- Company Age 17 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.30 M
as on 16-12-2024
- Revenue -39.33%
(FY 2022)
- Profit -882.26%
(FY 2022)
- Ebitda -94.16%
(FY 2022)
- Net Worth -19.19%
(FY 2022)
- Total Assets -18.27%
(FY 2022)
About Venus Bioceuticals
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.50 M and a paid-up capital of Rs 5.10 M.
The company currently has active open charges totaling ₹3.30 M.
Kishore Shah and Vinika Shah serve as directors at the Company.
- CIN/LLPIN
U74900MH2007PTC170818
- Company No.
170818
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 May 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Venus Bioceuticals Private Limited offer?
Venus Bioceuticals Private Limited offers a wide range of products and services, including Dinnerware and Serving Utensils, Drinking Glasses, Ayurvedic, Herbal Oils and Cosmetics, Ayurvedic Cosmetics.
Who are the key members and board of directors at Venus Bioceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kishore Shah  | Director | 15-May-2007 | Current |
| Vinika Shah | Director | 11-Apr-2008 | Current |
Financial Performance of Venus Bioceuticals.
Venus Bioceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 39.33% decrease. The company also saw a substantial fall in profitability, with a 882.26% decrease in profit. The company's net worth observed a substantial decline by a decrease of 19.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Venus Bioceuticals?
Unlock access to Venus Bioceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 Dec 2013 | ₹3.30 M | Open |
How Many Employees Work at Venus Bioceuticals?
Venus Bioceuticals has a workforce of 14 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Venus Bioceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Venus Bioceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
